You just read:

First Patient Dosed in Sintilimab and Anti-VEGF Monoclonal Antibody IBI305 with Chemotherapy in Patients with EGFR-mutant Non-squamous NSCLC who have Progressed from Prior EGFR-TKI Treatment

News provided by

Innovent Biologics, Inc.

Jul 24, 2019, 20:16 ET